MPE webinar: Long-term outcomes of CAR T-cell therapy in myeloma
Latest news
Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after treatment.
To inform myeloma patients and the myeloma community about the long-term benefits and side effects of CAR T-cell therapies, Myeloma Patients Europe (MPE) will host the webinar on “Long-term outcomes of CAR T-cell therapy in myeloma” on Wednesday, 21 October at 16:00 CEST.
During this webinar you will hear about the long-term efficacy and safety data from clinical trials of CAR T-cell therapies in myeloma, and what recovery, long term monitoring and side-effect management may look like. This presentation will be given by Dr. Herman Einsele, from the University of Würzburg in Germany, who is a myeloma expert with extensive experience in CAR T-cell therapies.
You will also hear from David Williams, a myeloma patient and Myeloma UK (MUK) member, who received CAR T-cell therapy three years ago. David will share his experiences, including preparation, outcomes, side effects, and quality of life.
The two presentations will be followed by a Q&A session, during which you will have the opportunity to ask both speakers your questions.
Whether you are a patient, a carer or a patient advocate, this webinar will help you stay informed and better understand myeloma CAR T-cell therapy and its long-term outcomes.
Should you be unable to attend the webinar, please feel free to send your questions in advance to info@mpeurope.org and we will make sure they reach our speakers. A recording of the webinar will be available shortly after the session. Keep an eye out for our social media profiles! We look forward to your participation.
Meet our speakers
Dr. Herman Einsele is Full Professor of Internal Medicine and Director of the Department of Internal Medicine II, University Hospital Würzburg, Germany since 2004. Since 2018, he is the chair of the Specialized Working Group on Immune Therapies for Hematologic Disorders of the European Hematology Association (EHA).
Dr. Einsele is an expert in the field of myeloma with focus on CAR T-cell therapy, bispecific antibodies, adoptive immunotherapy and stem cell transplantation.
David Williams is a myeloma patient and part of the MPE member organisation Myeloma UK (MUK). He was diagnosed with myeloma in October 2022 and was admitted on the sponsored CAR T-cell therapy clinical trial called CARTITUDE. He has been in remission since October 2023.
David is almost retired and lives with his wife in Bristol, UK. He has a daughter and son and four grandchildren. Learn more about David’s story here.